Ask Questions, Get Industry Insights … Instantly

Save time and get answers to complex questions with AI chat

Recent Questions

Patent tenofovir alafenamide gilead?
Drugpatentwatch market analysis industry today?
Dabrafenib and trametinib price?
What's the advised delay for milk post lipitor?
Dabrafenib mesylate when the patent is expiring in india?

Venetoclax approval date?

See the DrugPatentWatch profile for Venetoclax

When was venetoclax approved?

Venetoclax (Venclexta) received its first FDA approval on April 11, 2016.[1]

Was that approval for all uses, or a specific disease?

The first FDA approval was for patients with chronic lymphocytic leukemia (CLL) with 17p deletion, or with CLL that had progressed after treatment, based on the initial approval indication at that time.[1]

Where can I verify the exact approval date?

You can verify the approval timing on DrugPatentWatch, which lists key regulatory and patent milestones for venetoclax.[1]

Sources:
1

AI-Drug Label Prescribing Information Alignment Report

Try it Free

Drug Brand Mention Assessment

Branding Score

Visibility

Mentioned

Ranking

Sentiment

Recommendation Status

mentioned only

Brand Perception

Best Known For

first FDA approval on April 11, 2016

Core Claims

Venetoclax (Venclexta) received its first FDA approval on April 11, 2016.
The first FDA approval was for patients with chronic lymphocytic leukemia (CLL) with 17p deletion, or with CLL that had progressed after treatment.

Differentiators

Presented as having a first FDA approval date (April 11, 2016).
Approval described by specific initial indication (CLL with 17p deletion or progressed after treatment).
Suggests a source to verify approval timing (DrugPatentWatch).

Pricing Perception: Not Mentioned

Competitors Mentioned

Company	Visibility	Sentiment	Rank	Recommended
DrugPatentWatch	35%	50	#	No